Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

About this update from Gossamer Bio, Inc.

Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing expected to provide aggregate gross proceeds of up to approximately $250 million, before deducting placement agent fees and estimated offering expenses. The private placement consists of an initial closing, a committed second closing contingent upon FDA acceptance of the seralutinib new drug application (NDA) in PAH (the NDA Acceptance Milestone) and warrants exercisable upon FDA approval of seralutinib in PAH (the FDA Approval Milestone). The financing follows the Company’s recent reacquisition of worldwide rights to seralutinib and is in advance of the planned NDA submission in September 2026. The private placement includes $150 million of committed capital, consisting of approximately $25 million to be funded at the initial closing and an additional approximately $125 million to be funded at a second closing upon FDA acceptance of the seralutinib NDA in PAH. The investors’ obligations to fund the second closing remain subject to the NDA Acceptance Milestone occurring in 2026 and the satisfaction of other customary closing conditions. If the NDA Acceptance Milestone occurs in 2026, the Company expects to receive the full $150 million of committed capital in 2026. The private placement includes participation from new and existing institutional investors, including EcoR1 Capital, 683 Capital Partners, LP, RA Capital Management, Coastlands Capital, Samsara BioCapital and Rock Springs Capital, among others. “This financing is expected to provide the capital needed to advance seralutinib through potential FDA approval in PAH,” said Faheem Hasnain, Chairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “The committed funding structure aligns capital availability with key regulatory milestones and is expected to support the planned submission and review of our NDA. We appreciate the support of this group of leading healthcare investors as we work to bring a potentially important new trea...

View stock analysis, news, and events for Gossamer Bio, Inc.